Closing the cycle of innovation in health care in Europe

17 January 2020 - Pragmatic or practice-oriented comparative effectiveness trials may be conducted to fill the evidence gaps that are revealed ...

Read more →

Europe and Norway discuss improving affordable access to innovative medicines

16 January 2020 - All countries across the WHO European Region face a challenge in ensuring that high-value but expensive ...

Read more →

Isturisa (osilodrostat) approved

15 January 2020 - Recordati announces that the European Commission has granted marketing authorisation for the orphan medicinal product Isturisa (osilodrostat), ...

Read more →

Janssen seeks expanded use of Spravato (esketamine) nasal spray in Europe as a treatment for depressive symptoms in adults with major depressive disorder who have current suicidal ideation with intent

15 January 2020 - In two pivotal Phase 3 trials, Spravato combined with comprehensive standard of care achieved statistically significant ...

Read more →

Differences in health technology assessment recommendations among European jurisdictions: the role of practice variations

14 January 2020 - HTA recommendations vary widely throughout Europe, even for the same medicine. ...

Read more →

PTC Therapeutics provides corporate update

13 January 2020 - PTC-AADC MAA submitted; BLA now expected to be submitted in 2Q 2020. ...

Read more →

Sanofi secures expanded European approval for Toujeo in type 1 diabetes

10 January 2020 - Sanofi has revealed that the European Commission has expanded the existing label for Toujeo (insulin glargine ...

Read more →

Acerus provides update on Natesto approval process in Europe

10 January 2020 - Acerus Pharmaceuticals today announced that the dossier filed as a decentralised Procedure in 19 European countries ...

Read more →

ViiV Healthcare submits regulatory application to the European Medicines Agency for fostemsavir, an investigational, first-in-class attachment inhibitor for the treatment of HIV in adults with few treatment options available

10 January 2020 - ViiV Healthcare with Pfizer and Shionogi, today announced the submission of a marketing authorisation application to ...

Read more →

Defending transparency at European drug regulator

8 January 2020 - Forthcoming judgment must uphold public access to clinical data ...

Read more →

Human medicines: highlights of 2019

9 January 2020 - EMA has published a review of its key recommendations in 2019 on the authorisation and safety ...

Read more →

Incyte announces the validation by the European Medicines Agency of its marketing authorisation application for pemigatinib in patients with cholangiocarcinoma

7 January 2020 - Incyte today announced the validation of the Company’s marketing authorisation application for pemigatinib for the treatment of ...

Read more →

Kyowa Kirin announces marketing authorisation application for istradefylline validated by European Medicines Agency

6 January 2020 - Kyowa Kirin today announces that its marketing authorisation application for istradefylline (KW-6002) as an adjunctive treatment ...

Read more →

Beyond “Intent‐to‐treat” and “Per protocol”: improving assessment of treatment effects in clinical trials through the specification of an estimand

27 December 2019 - There is a key problem in randomised clinical trials as outcomes can be distorted due to ...

Read more →

EMA accepts regulatory submission for Lumoxiti in relapsed or refractory hairy cell leukaemia

2 January 2020 - Innate Pharma today announced that the EMA has accepted the marketing authorisation application for Lumoxiti (moxetumomab ...

Read more →